- Home
- PVL vs NSRX Comparison
PVL vs NSRX Comparison
Compare PVL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- NSRX
- Stock Information
- Founded
- PVL 2011
- NSRX 2019
- Country
- PVL United States
- NSRX Israel
- Employees
- PVL N/A
- NSRX N/A
- Industry
- PVL Oil & Gas Production
- NSRX Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- NSRX Health Care
- Exchange
- PVL Nasdaq
- NSRX Nasdaq
- Market Cap
- PVL 57.8M
- NSRX 65.7M
- IPO Year
- PVL N/A
- NSRX 2025
- Fundamental
- Price
- PVL $1.79
- NSRX $7.00
- Analyst Decision
- PVL
- NSRX Strong Buy
- Analyst Count
- PVL 0
- NSRX 1
- Target Price
- PVL N/A
- NSRX $22.00
- AVG Volume (30 Days)
- PVL 82.4K
- NSRX 3.3K
- Earning Date
- PVL 01-01-0001
- NSRX 12-09-2025
- Dividend Yield
- PVL 19.89%
- NSRX N/A
- EPS Growth
- PVL N/A
- NSRX N/A
- EPS
- PVL 0.06
- NSRX N/A
- Revenue
- PVL $3,511,891.00
- NSRX N/A
- Revenue This Year
- PVL N/A
- NSRX N/A
- Revenue Next Year
- PVL N/A
- NSRX N/A
- P/E Ratio
- PVL $27.17
- NSRX N/A
- Revenue Growth
- PVL 11.77
- NSRX N/A
- 52 Week Low
- PVL $1.30
- NSRX $5.90
- 52 Week High
- PVL $2.04
- NSRX $9.99
- Technical
- Relative Strength Index (RSI)
- PVL 51.08
- NSRX N/A
- Support Level
- PVL $1.76
- NSRX N/A
- Resistance Level
- PVL $1.86
- NSRX N/A
- Average True Range (ATR)
- PVL 0.06
- NSRX 0.00
- MACD
- PVL -0.00
- NSRX 0.00
- Stochastic Oscillator
- PVL 53.85
- NSRX 0.00
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.